Searchable abstracts of presentations at key conferences in endocrinology

ea0011p87 | Clinical case reports | ECE2006

Gitelman’s syndrome in pregnant, type 1 diabetic patient presented with foetal growth retardation, and bilateral hydronephrosis and hydroureter

Elrishi MA , Kilvert A , Sirnivasan B , Lawrence I

GitelmanÂ’s syndrome (GS) is an autosomal recessive primary renal tubular disorder with hypokalemic metabolic alkalosis, hypocalciuria, and magnesium deficiency. The association of GS and type 1 diabetes is rare1, and bilateral hydronephrosis and hydroureter has not been reported.A 18-year-old female with known GS diagnosed at 17 years of age and type 1 diabetes diagnosed at 15 years of age was admitted to Leicester Royal Infirmary for pre...

ea0011p139 | Clinical case reports | ECE2006

Multihormonal disorders in 17 year old girl with congenital hypoplastic anemia and secondary hemochromatosis

Glab E , Wikiera B , Barg E

Congenital hypoplastic anemia (Diamond-Blakfan Syndrom) is genetically determined disorder which is manifested in early childhood with selective deficiency of erythrocyte line in bone marrow. Severe anemia usually appears between 2nd and 6th month of life. Survival depends on blood transfusions, which in consequence lead to hemosiderosis. Hypopituitarism, hypogonadism and diabetes mellitus and other endocrinopathies are the complications of hemochromatosis.<p class="abstex...

ea0011p173 | Clinical case reports | ECE2006

Pretibial Myxoedema: Is this a marker for occult thyroid ophthalmopathy?

Bhattacharya B , Ullah A , McCulloch AJ , Heald AH

Introduction: Thyroid eye disease affects an estimated 400,000 people in the UK and for a sizeable minority this is an extremely unpleasant condition. Radioactive iodine treatment with I131 for thyrotoxicosis can cause sight-threatening flare-up of dysthyroid eye disease. Patients with dysthyroid eye signs should undergo specialist ophthalmology assessment prior to administration of I131.Case history: A 56 year old gentleman presented with symptoms of th...

ea0011p582 | Neuroendocrinology and behaviour | ECE2006

Hypopituitary patients have a high occurrence of metabolic syndrome markers and an increased prevalence of cardiovascular risk factors

Matuszek B , Obel E , Kowalczyk M , Nowakowski A

Introduction: Hypopituitary patients receiving conventional hormone substitution, but without GH replacement, have an increased mortality from cardiovascular diseases. Inadequate hormone replacement is a possible cause of this increased mortality. GH deficiency in adult patients has been associated with several cardiovascular risk factors, including hyperlipidemia, increased abdominal adiposity, and impaired insulin sensitivity.Aim of the study: The aim ...

ea0057031 | TSH receptor-blocking autoantibodies: the pregnancy paradigm | BES2018

TSH receptor-blocking autoantibodies: the pregnancy paradigm

Martens P-J , Polders C , Decallonne B

Background: GravesÂ’ disease (GD) is an autoimmune disease caused by antibodies directed to the TSH receptor (TRAb), which can be activating (TSAb), neutral, or blocking (TBAb). This balance determines the final clinical result. Typically TSAbs dominate, resulting in hyperthyroidism. Rarely, TBAbs prevail and result in hypothyroidism (1). The TRAb assay routinely used in the clinic does not allow to differentiate between stimulating or blocking characteristics.<p class...

ea0010p85 | Steroids to include Cushing's | SFE2005

Adrenalectomy for hypercortisolism

Girardin E , Verges B , Brun J

Aim of the study: to analyze surgical outcome in patients who underwent unilateral or bilateral adrenalectomy for hypercortisolism.Methods: retrospective study including patients operated on between January 1994 and June 2005.Results: adrenalectomies for hypercortisolism were performed in 18 patients (5 males, 13 females, mean age 43.6±16.1 years). Indications were cortisol producing adenoma (n=10), adrenocortical carcinoma (n...

ea0009p14 | Diabetes and metabolism | BES2005

Effects of hormone replacement therapy and raloxifene on C-reactive protein in healthy postmenopausal women

Kumru S , Yildiz M , Godekmerdan A , Yilmaz B

We have investigated the effects of estradiol valerat plus dienogest and raloxifene on serum high sensitive C - reactive protein (hsCRP) levels in healthy postmenopausal women. This study was approved by the local ethics committee. Forty eight healthy postmenopausal women were randomly divided into three groups. While group I (n=16) was given 60 mg raloxifene, group II (n=16) received continuously 2 mg estradiol valerat plus 2 mg dienogest. Group III (n=16) received no medicat...

ea0009p95 | Endocrine tumours and neoplasia | BES2005

Diagnostic mutation testing in multiple endocrine neoplasia type 1 (MEN1): Support for the current referral criteria

Vaidya B , Owen M , Hattersley A , Ellard S

Background: Multiple Endocrine Neoplasia (MEN1) is an autosomal dominant disorder characterised by tumours of the parathyroids, pancreas and pituitary. Recent consensus guidelines have recommended screening of MEN1 gene mutations in patients who have at least two of the parathyroid hyperplasia, pancreatic endocrine tumour or pituitary adenoma, or are suspicious of having MEN1 (multiple parathyroid tumours before age 30, recurrent hyperparathyroidism, gastrinoma or multiple isl...

ea0009p141 | Steroids | BES2005

Chronic glucocorticoid excess does not cause fatty liver disease in mice

Raubenheimer P , Nyirenda M , Walker B

Case reports in humans implicate glucocorticoid (GC) excess, through exogenous administration or endogenous overproduction, as a cause of non-alcoholic fatty liver disease. In rodents, massive doses of GCs have induced fatty liver when liver fat was measured in the fasting state. The mechanisms through which GCs might induce fatty liver are unknown, but are thought to be secondary to insulin resistance/hyperinsulinaemia. In this study, we examined the effect of dexamethasone (...

ea0009p144 | Steroids | BES2005

Increased 5alpha-reductase activity during the luteal phase of the normal menstrual cycle

Quinkler M , Hughes B , Stewart P

During the luteal phase of the menstrual cycle aldosterone increases mainly due to the antagonistic properties of progesterone at the MR and due to estrogen-mediated stimulation of angiotensinogen. Little is known about other steroid-metabolizing enzymes that may influence steroid receptor binding, eg 11beta-HSDs, A-ring reductases. Therefore a group of ten normotensive female volunteers with regular menstrual cycles were studied on day 7 (follicular phase) and day 21 (luteal ...